Cargando…

First-line ICIs in renal cell carcinoma

Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-α) and high-dose interleukin−2 (HD IL−2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiorentino, Vincenzo, Tralongo, Pietro, Larocca, Luigi Maria, Pizzimenti, Cristina, Martini, Maurizio, Pierconti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Immunotherapy - Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332208/ https://www.ncbi.nlm.nih.gov/pubmed/37395601 http://dx.doi.org/10.1080/21645515.2023.2225386

Ejemplares similares

Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

DOG1 as an Immunohistochemical Marker of Acinic Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Fiorentino, Vincenzo, et al.
Publicado: (2022)

A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights
por: Fiorentino, Vincenzo, et al.
Publicado: (2022)

Unusual localization and clinical presentation of primary central nervous system extranodal marginal zone B‑cell lymphoma: A case report
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
por: DeBenedette, Mark, et al.
Publicado: (2023)

Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report
por: Fiorentino, Vincenzo, et al.
Publicado: (2019)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
por: Awasthi, Rakesh, et al.
Publicado: (2023)

Identification of key immune cell-related genes involved in tumorigenesis and prognosis of cervical squamous cell carcinoma
por: Yan, Chunxiao, et al.
Publicado: (2023)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2021)

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
por: Cortellini, Alessio, et al.
Publicado: (2020)

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2021)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
por: D'Angelo, Sandra P, et al.
Publicado: (2021)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

Melanoma stem cell vaccine induces effective tumor immunity against melanoma
por: Yin, Qiliang, et al.
Publicado: (2023)

Adjuvant DNA vaccine pNMM promotes enhanced specific immunity and anti-tumor effects
por: Wang, Yu, et al.
Publicado: (2023)

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022
por: Chen, Yizhen, et al.
Publicado: (2023)

Profile EpicentRx, Inc
por: Oronsky, Bryan
Publicado: (2023)

Global research trends on immunotherapy in cancer: A bibliometric analysis
por: Yao, Zhichao, et al.
Publicado: (2023)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)
por: Huang, Xiaojuan, et al.
Publicado: (2023)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis
por: Zhao, Juan, et al.
Publicado: (2023)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

Bibliometric analysis of RNA vaccines for cancer
por: Yang, Xue, et al.
Publicado: (2023)

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
por: Martini, Maurizio, et al.
Publicado: (2018)

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
por: Abou Alaiwi, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k72mbkj0t6euhq30djjvbaq965